Should I sell Acadia Pharmaceuticals?
ACADIA Pharmaceuticals has received a consensus rating of Hold. The company’s average rating score is 2.39, and is based on 7 buy ratings, 11 hold ratings, and no sell ratings.
Will Acadia Pharmaceuticals stock go up?
Stock Price Forecast The 19 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 30.00, with a high estimate of 42.00 and a low estimate of 20.00. The median estimate represents a +15.56% increase from the last price of 25.96.
Why did Acadia Pharmaceuticals stock drop?
Why This Acadia Pharmaceuticals Move Has Analysts Split — And Shares Down 20% Acadia Pharmaceuticals (ACAD) will ask the Food and Drug Administration to approve a once-rejected psychosis drug, but ACAD stock plunged on Tuesday. The FDA previously rejected Acadia’s Nuplazid as a treatment for dementia-related psychosis.
What does Acadia Pharmaceuticals make?
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders.
Is ACAD stock a good buy?
Out of 17 analysts, 1 (5.88%) are recommending ACAD as a Strong Buy, 5 (29.41%) are recommending ACAD as a Buy, 11 (64.71%) are recommending ACAD as a Hold, 0 (0%) are recommending ACAD as a Sell, and 0 (0%) are recommending ACAD as a Strong Sell. What is ACAD’s earnings growth forecast for 2022-2024?
Is Acadia a good company?
Is Acadia Pharmaceuticals a good company to work for? Acadia Pharmaceuticals has an overall rating of 4.1 out of 5, based on over 23 reviews left anonymously by employees. Employees also rated Acadia Pharmaceuticals 3.7 out of 5 for work life balance, 4 for culture and values and 3.6 for career opportunities.
Is Acadia stock a good buy?
ACADIA Pharmaceuticals Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of ACAD, demonstrate its potential to underperform the market. It currently has a Growth Score of A.
Why is Acadia stock going up?
Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biotech company that focuses on neuroscience therapies, saw its shares rise 10.6% on Wednesday. It plans to resubmit its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin), as a treatment for hallucinations and delusions associated with dementia.
How many employees does Acadia have?
Acadia Pharmaceuticals
| Formerly | Receptor Technologies |
|---|---|
| Total equity | US$699.14 million (2019) |
| Number of employees | 570 (June 30, 2020) |
| Website | acadia-pharm.com |
| Footnotes / references |
How many employees does Acadia Pharmaceuticals have?
570Acadia Pharmaceuticals / Number of employees (June 30, 2020)
When did ACAD go public?
IPO and further growth On October 2020, Academy launched an IPO and became a public company listed on the Nasdaq with the ticker symbol ASO. After going public, a continued national expansion plan was laid out calling for 8-10 stores per year starting in 2022.
Who owns Acadia Healthcare?
Waud Capital Partners
Acadia Healthcare, Majority Owned by Waud Capital Partners, Completes Merger with PHC, Inc. and Becomes Publicly Traded Company. Chicago, IL, November 1, 2011 ─ Waud Capital Partners (“WCP”), a Chicago based middle-market private equity firm, today announced that Acadia Healthcare Company, Inc.